Abstract

BackgroundSubcutaneous tocilizumab (TCZ-SC) has demonstrated non-inferiority to TCZ-IV and superiority to placeboObjectivesThe primary objective of this study was to assess the 24-week efficacy and safety of subcutaneous (SC) tocilizumab (TCZ)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
SAT0105 Summacta: A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy Of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients With Moderate to Severe Ra
G R Burmester ... E Mysler
Annals of the Rheumatic Diseases | VOL. 72
G R Burmester, et. al.G R Burmester ... E Mysler
01 Jun 2013
THU0314 OUTCOMES OF PATIENTS TREATED WITH TOCILIZUMAB OR ABATACEPT AS STEROID-SPARING AGENTS WITH GIANT CELL ARTERITIS
Elena Rubini ... Daniela Rossi
-
Elena Rubini, et. al.Elena Rubini ... Daniela Rossi
01 Jun 2019
AB0666 Clinical and serological outcomes of patients with giant cell arteritis treated with tocilizumab or abatacept as steroid-sparing agents
S Sciascia ... I Cecchi
Annals of the Rheumatic Diseases | VOL. 77
S Sciascia, et. al.S Sciascia ... I Cecchi
01 Jun 2018
POS0530 MOLECULAR SIGNATURE IN SUSTAINED CLINICAL REMISSION INDUCED BY TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
K Matsumoto ... K Suzuki
-
K Matsumoto, et. al.K Matsumoto ... K Suzuki
23 May 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers